Tetrahydroacridinone Analogues for Malaria Treatment and Prevention
Summary
The USPTO published patent application US20260098012A1 for tetrahydroacridinone scaffold molecules exhibiting antimalarial activity against multiple Plasmodium spp. strains in erythrocytic and exoerythrocytic stages. The application, filed December 11, 2025, names 11 inventors including Dennis E. Kyle and Steven Maher and covers pharmaceutical compositions for malaria treatment and prevention.
What changed
The USPTO published patent application US20260098012A1 disclosing tetrahydroacridinone scaffold molecules with antimalarial activity against multiple Plasmodium spp. strains including both erythrocytic and exoerythrocytic stages. The compounds are covered under CPC classifications C07D 219/06, A61K 31/473, A61P 33/06, and related compound classes C07D 401/04, 405/04, 409/04, 417/04.
Pharmaceutical companies developing antimalarial drugs should review this patent application for potential licensing opportunities or freedom-to-operate concerns. The patent claims cover pharmaceutical compositions comprising the disclosed tetrahydroacridinone analogues for treating or preventing malaria in subjects. Compound novelty and therapeutic efficacy across multiple parasite stages may present opportunities for collaboration with the named inventors.
What to do next
- Monitor for patent prosecution updates
- Review compound claims for freedom-to-operate analysis
- Assess licensing opportunities for malaria treatment development
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA
Application US20260098012A1 Kind: A1 Apr 09, 2026
Inventors
Dennis E. KYLE, Steven MAHER, Ami H. Asakawa, Khaly D. Diagne, Roman Manetsch, Adriana A. Marin, Anthony Marasciullo, Caroline E. Consoli, Sagan Thomas de Castro, Olivia Isabelle McWhorter, Meng CUI
Abstract
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that exhibit potent antimalarial activity against multiple strains of Plasmodium spp. in the parasite's various stages, such as, for example, the erythrocytic and exoerythrocytic stages, and pharmaceutical compositions comprising same. In one aspect, the compounds are tetrahydroacridinones having the structure I described herein. In another aspect, the compounds described herein can be used to treat or prevent malaria in a subject.
CPC Classifications
C07D 219/06 A61K 31/473 A61P 33/06 C07D 401/04 C07D 405/04 C07D 409/04 C07D 417/04
Filing Date
2025-12-11
Application No.
19416056
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.